Abstract
Tetracyclines (TCNs) are commonly used in the management of several chronic dermatological disorders, partly due to their affinity for inflamed skin tissue, as they are known to suppress cytokines including tumor necrosis factor-alpha and interleukin-6 that are typically involved in inflammatory skin disorders.1 TCNs are known to be photoreactive following ultraviolet (UV) radiation exposure, a known risk factor for the development of nonmelanoma skin cancer (NMSC), notably basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).2 Previous studies examining the relationship between photoreactive medications, including psoralen compounds and sulfonamide moieties, and NMSC suggest an association.
This article is protected by copyright. All rights reserved.
http://ift.tt/2rnOVj0
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου